FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to binding CD47 proteins; it can be used in medicine for therapy of CD47-positive hematological tumors and CD47-positive solid tumors, as well as autoimmune diseases, such as Crohn’s disease, allergic asthma, and rheumatoid arthritis.
EFFECT: proposed invention provides obtainment of protein, which has following characteristics: 1) specific binding to CD47 protein with relatively high affinity; 2) specific blocking of interaction of CD47 protein with SIRPalpha; 3) it does not cause blood clotting reaction; 4) inhibition of growth and/or proliferation of tumors or tumor cells; 5) blocking of an apoptotic signal induced by interaction of CD47/SIRPalpha; and/or 6) it is safe for a human and does not have side effects causing damage to the body.
15 cl, 20 dwg, 2 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTIBODIES TO PROTEIN CD38, AND THEIR USE | 2019 |
|
RU2776795C2 |
| EMBODIMENTS OF SIRP-ALPHA-4-1BBL FUSION PROTEIN AND METHODS OF USE THEREOF | 2019 |
|
RU2815515C2 |
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| IMMUNOMODULATORY FUSED PROTEINS AND THEIR APPLICATION METHODS | 2016 |
|
RU2755227C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
